| Similar Articles |
|---|
 |
Bio-IT World
June 2005 |
News Blast On the Move: Alex Kotzer will join Compugen... Change of Guard: Stephen P. DeFalco, chairman and CEO of U.S. Genomics... A Funding Find: Mitsui USA has invested $5 million in Gentris... etc.   |
Bio-IT World
January 13, 2003
John Dodge |
Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets. |
Bio-IT World
May 7, 2002
Malorye Branca |
In Silico Survivors Facing desperate times, bioinformatics companies revamp, refocus, or perish. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
Bio-IT World
July 14, 2004
Davies & Russell |
The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology. |
Bio-IT World
March 2006 |
News Blast X Prize... Junk Discovery... Susceptibility... Resistance... |
